AEMD

Over the past six months, Aethlon Medical, Inc.'s stock price has decreased by 45.24%, and over the past year, it has dropped by 92.43%. In March 2026, Aethlon Medical announced that all previously outstanding pre-funded warrants had been exercised, resulting in 1,569,110 shares of common stock outstanding. In March 2026, the company engaged Maxim Group LLC to evaluate strategic opportunities, including potential partnerships, mergers, and acquisitions. Also in March 2026, Aethlon Medical advanced to the final cohort in its oncology clinical trial following a positive DSMB review. In February 2026, the company presented at the Emerging Growth Conference and announced its fiscal Q3 2026 financial results and corporate update. In November 2025, Aethlon Medical held its Second Quarter 2026 Investor Call.